Eli Lilly's Strategic Bet on Sleep Disorder Therapies
PILLAR DIAGNOSTIC // WEEK 14
“The announced Lilly–Centessa deal faces no binding regulatory or financing hurdles, while the post‐announcement breakout and institutional flows aren’t yet fully reflected in retail sentiment. As milestone CVRs approach and sentiment catches up, shares should grind higher toward the $44–56 zone.”
Proposed action
Accumulate on dips
THE MECHANICS
Tape & flow
Centessa ($CNTA) surged 45% after breaking out above $25, approaching profit-taking zones near $40 with potential extensions to $44 and $56 amid expectations of consolidation and short-term pullbacks.
THE MACHINE
Operational momentum
Eli Lilly is expanding its sleep disorder therapy pipeline by acquiring Centessa Pharmaceuticals for $38 per share in cash plus one contingent value right, valuing the base deal at $6.3 billion and up to $47 per share if milestones are met.
THE MAP
Structure & constraints
Eli Lilly will acquire Centessa Pharmaceuticals by paying $38 in cash per share plus non-transferrable contingent value rights, valuing the transaction at $6.3 billion upfront and up to $7.8 billion with milestones to secure Centessa’s OX2R agonist pipeline for sleep-wake disorder treatments.
THE MOOD
Consensus & positioning
Eli Lilly’s takeover of Centessa has generated upbeat chatter, centered on a 38% cash premium and up to $7.8 billion valuation with contingent payments, driving speculative enthusiasm and curiosity as investors await a Q3 closing.